New drug aims to heal hearts after major attack
NCT ID NCT07586865
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called NL005 in people who have had a severe type of heart attack (STEMI) and undergone emergency artery-opening treatment. The goal is to see if NL005 can reduce permanent heart muscle damage. Participants will receive either NL005 or a placebo daily for 7 days and be monitored for a year with scans and checkups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human thymosin beta 4 (NL005)
What this could lead to
If it works, this could lead to a treatment that reduces permanent heart muscle damage after a severe heart attack, potentially improving recovery and lowering the risk of heart failure.
What could go wrong
This is an early Phase IIc trial with only 189 participants, so results may not apply to everyone. The drug is experimental, and its safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)
Beijing, Beijing Municipality, 100037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••